cancer

Astellas announced that China NMPA approved XTANDI for the treatment of prostate cancer

The FINANCIAL — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has approved XTANDI® (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high
November 6, 2020
2 mins read

Is 5G dangerous for health?

The FINANCIAL — Parts of the community are concerned about the safety of 5G network. Could it pose health risks? The International Commission on Non‐Ionizing Radiation Protection (ICNIRP) has released new guidelines for the protection of humans exposed to radiofrequency electromagnetic fields.
March 13, 2020
2 mins read

Get updates

Join

We hate spams like you do

Latest comments

Go toTop